Cancer News
Comet Portfolio: Enabling Complete and Inclusive Spatial Biology
CAR-T Cell Therapy Shows Promise Against Small Cell Lung Cancer
Breyanzi CAR-T therapy receives positive CHMP opinion for R/R LBCL
Empowering Ethnic Minorities for Colorectal Cancer Screening
Combination Therapy Restores Blood Cancer Treatment Efficacy
Racial Disparities in Cancer Patients' 2023 Diabetes Diagnosis
Role of SOX9 Protein in Colorectal Cancer Progression
CAR-T Cell Advancements in Therapy for Targeting Heterogeneity: mCRPC
Polatuzumab Vedotin Shows Promise in DLBCL: POLARIX Trial
Tafasitamab: Final Results of 5-year study on DLBCL
How Can Focal Adhesion Kinase, Fibroblasts, and C-X-C Chemokine Help?
Next Oncology Expanded Phase 1 Program Cancer Drug Research in Dallas
Long-Term SAR408701 Treatment in NSQ NSCLC CEACAM5 Safety and Efficacy
CAR-T Cell Therapy for B-Cell Malignancies: A Longitudinal Study
DecisionRT Tool to Guide Endocrine Therapy after BCS for Breast Cancer
Platinum Chemotherapy vs. Temozolomide/Capecitabine: Advanced GEPNENs
Taking on KRAS in Lung Cancer: Promising Advances in Targeted Therapy
Pathologic Complete Response: I-SPY2 Trial Insights
T-Vec and Pembrolizumab Combination the Masterkey-115 Trial
Lisaftoclax for CLL/SLL: Monotherapy, Acalabrutinib, or Rituximab?
Trimodality Approach for HER2+ Esophageal Adenocarcinoma Shows Promise
Acalabrutinib (AVO): Triplet Therapy in High-Risk CLL
MDS Real-world Study [2023] Treatment Patterns and Survival USOncology - Ira Zackon MD
Evaluating Allogeneic Hematopoietic Cell Transplantation: ASAP Trial
Idecabtagene Vicleucel Shows Promise in High-Risk Multiple Myeloma
Odronextamab: breakthrough for RR follicular lymphoma? Phase II ELM-2
REGN5458 Trial Shows Promise in Relapsed/Refractory Multiple Myeloma
EGFR Mutations: Latest Advanced Treatments for Lung Cancer in 2023
Urothelial Cancer: What's New in 2023? Dr. Nataliya Mar
Mosunetuzumab: A Review - Promising New Therapy for Lymphoma
Lung Cancer EGFR: Latest Clinical Trials Insights from Dr. Ravi Salgia
Gastrointestinal Malignancies Advancements in Research
Health Inequity Examining and Uncovering Disparities in Healthcare
Zanubrutinib Outperforms Ibrutinib in PFS for RR CLL/SLL: ALPINE Trial
Renal Cell Carcinoma Trials: Guidelines & Eligibility ASCO-FCR Trials
Renal Cell Carcinoma Trials: ASCO-FCR Guidelines RCC Trial Eligibility
HER2-Low Breast Cancer: ADCs for 2023: Novel Drug Antibody Conjugates
Belzutifan: A Groundbreaking Kidney Cancer Breakthrough with Dr. Rana McKay
Liso-cel: ASH 2022 vs SOC SCT and ASCT in RR LBCL
MRD: ASH 2022 the MRD2STOP Guide
Isatuximab: ASH 2022 Phase 3 Ithaca Study
Anti-CD38: ASH 2022 Treatment Patterns and Pt Outcomes
Pembro: ASH 2022 After auto-SCT in T-Cell NHL
MPN: ASH 2022 Add-on of Parsaclisib
PTG-300: ASH 2022 Verify Phase 3 Clinical Trial
Pembro: ASH 2022 After Auto-SCT T-Cell NHL
ASCO [2022] Breast Cancer & Melanoma Video Overviews: MOASC Spotlight
BRCA1, BRCA2 or PALB2 in Pancreatic Cancer
DetermaIO algorithm and qPCR assay
HER3 and Seribantumab and the CRESTONE Data
ASCO Top 3 Trending Interviews - June 5th, 2022 - eNewsletter Blog
Top Trending Oncology News Week Ending June 19, 2022
All posts
Subscribe to Email Updates
Recent
Popular
Categories
Lists by Topic
ASH
(12)
MOASC
(9)
City of Hope
(6)
Interview
(5)
Lymphoma
(5)
ASCO22
(4)
B-cell Lymphoma
(3)
Chronic Lymphocytic Leukemia
(3)
Gastrointestinal Malignancies
(3)
Immunotherapy
(3)
Lung Cancer EGFR
(3)
ASCO FCR Guidelines
(2)
Breast Cancer
(2)
Kidney Cancer
(2)
Ravi Salgia
(2)
Renal Cell Carcinoma
(2)
Thoracic Oncology
(2)
UC Irvine
(2)
Acute Myeloid Leukemia
(1)
Antibody Conjugates
(1)
CAR T-cell
(1)
Ethnic Minorities
(1)
Follicular Lymphoma
(1)
HER2 low
(1)
Health Inequity
(1)
Mehrdad Mobasher
(1)
Mosunetuzumab
(1)
Multiple Myeloma
(1)
Nataliya Mar
(1)
Odronextamab
(1)
Oncocyte
(1)
Penn Medicine
(1)
SABCS
(1)
Small Cell Lung Cancer
(1)
Small Lymphocytic Leukemia
(1)
Trial Eligibility
(1)
UCSF
(1)
Urothelial Cancer
(1)
Yuan Yuan
(1)
Zanubrutinib
(1)
belzutifan
(1)
idecabtagene vicleucel
(1)
see all
Posts by Topic
ASH
(12)
MOASC
(9)
City of Hope
(6)
Interview
(5)
Lymphoma
(5)
ASCO22
(4)
B-cell Lymphoma
(3)
Chronic Lymphocytic Leukemia
(3)
Gastrointestinal Malignancies
(3)
Immunotherapy
(3)
Lung Cancer EGFR
(3)
ASCO FCR Guidelines
(2)
Breast Cancer
(2)
Kidney Cancer
(2)
Ravi Salgia
(2)
Renal Cell Carcinoma
(2)
Thoracic Oncology
(2)
UC Irvine
(2)
Acute Myeloid Leukemia
(1)
Antibody Conjugates
(1)
CAR T-cell
(1)
Ethnic Minorities
(1)
Follicular Lymphoma
(1)
HER2 low
(1)
Health Inequity
(1)
Mehrdad Mobasher
(1)
Mosunetuzumab
(1)
Multiple Myeloma
(1)
Nataliya Mar
(1)
Odronextamab
(1)
Oncocyte
(1)
Penn Medicine
(1)
SABCS
(1)
Small Cell Lung Cancer
(1)
Small Lymphocytic Leukemia
(1)
Trial Eligibility
(1)
UCSF
(1)
Urothelial Cancer
(1)
Yuan Yuan
(1)
Zanubrutinib
(1)
belzutifan
(1)
idecabtagene vicleucel
(1)
See all
Recent Posts
